A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

INTRODUCTION: Fulvestrant shows dose-dependent biological activity. Greater estrogen-receptor (ER) blockade may feasibly be achieved by combining fulvestrant with anastrozole. This pre-surgical study compared fulvestrant plus anastrozole versus either agent alone in patients with ER-positive breast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Robertson, John FR, Dixon, J Michael, Sibbering, D Mark, Jahan, Ali, Ellis, Ian O, Channon, Eddie, Hyman-Taylor, Pauline, Nicholson, Robert I, Gee, Julia MW
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672778/
https://ncbi.nlm.nih.gov/pubmed/23497452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3393
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars